Cancer Research and Treatment

Original Articles

The NEAT Predictive Model for Survival in Patients with Advanced Cancer: Amanda Zucker, Chiaojung Jillian Tsai, John Loscalzo, Pedro Calves, Johnny Kao; Cancer Res Treat. 2018;50(4):1433-1443. Published online January 24, 2018; DOI: https://doi.org/10.4143/crt.2017.223

Purpose
We previously developed a model to more accurately predict life expectancy for stage IV cancer patients referred to radiation oncology. The goals of this study are to validate this model and to compare competing published models.
Materials and Methods
From May 2012 to March 2015, 280 consecutive patientswith stage IV cancerwere prospectively evaluated by a single radiation oncologist. Patients were separated into training, validation and combined sets. TheNEAT model evaluated number of active tumors (“N”), Eastern Cooperative Oncology Group performance status (“E”), albumin (“A”) and primary tumor site (“T”). The Odette Cancer Center model validated performance status, bone only metastases and primary tumor site. The Harvard TEACHH model investigated primary tumor type, performance status, age, prior chemotherapy courses, liver metastases, and hospitalization within 3 months. Cox multivariable analyses and logisticalregressionwere utilized to compare model performance.
Results
Number of active tumors, performance status, albumin, primary tumor site, prior hospitalizationwithin the last 3 months, and liver metastases predicted overall survival on uinvariate and multivariable analysis (p < 0.05 for all). The NEAT model separated patients into four prognostic groups with median survivals of 24.9, 14.8, 4.0, and 1.2 months, respectively (p < 0.001). The NEAT model had a C-index of 0.76 with a Nagelkerke’s R2 of 0.54 suggesting good discrimination, calibration and total performance compared to competing prognostic models.
Conclusion
The NEAT model warrants further investigation as a clinically useful approach to predict survival in patients with stage IV cancer.

Citations

Citations to this article as recorded by

Nutritional care pathways in cancer patients with malignant bowel obstruction: A retrospective multi-centre study
Pinal S. Patel, Konstantinos Fragkos, Niamh Keane, David Wilkinson, Amy Johnson, Derek Chan, Bradley Roberts, Penny Neild, Metin Yalcin, Philip Allan, Michael E.B. FitzPatrick, Michael Gomez, Sarah Williams, Klaartje Kok, Lisa Sharkey, Carla Swift, Shamee
Clinical Nutrition ESPEN.2024; 59: 118. CrossRef
Predicting long‑term survival following involved site radiotherapy for oligometastases
Johnny Kao, Patricia Eckardt, Jennifer Mceachron, Christopher Atalla, Ashish Sangal
Oncology Letters.2024;[Epub] CrossRef
Palliative radiotherapy: survival prognostic factors - single-centre retrospective cohort study
Sian Cooper, Mary Denholm, Abdul Shawal Malek, Jeffrey Arun Rubasingham, David Tsang
BMJ Supportive & Palliative Care.2024; : spcare-2024-004810. CrossRef
Thirty‐day mortality after palliative radiotherapy in advanced cancer patients: Optimizing end‐of‐life care in Asia
Mi Sun Kim, Hyejung Cha, Sei Hwan You, Sunghyun Kim
Journal of Medical Imaging and Radiation Oncology.2024; 68(3): 307. CrossRef
Palliative Appropriateness Criteria: A Pragmatic Method to Evaluate the Suitability of Palliative Radiotherapy Fractionation
Joshua C. Farris, Adam G. Johnson, Patrick P. Carriere, Zachary A. Patel, Moeko Nagatsuka, Michael K. Farris, Ryan T. Hughes
Journal of Palliative Medicine.2023; 26(1): 67. CrossRef
The LabPS score
Carsten Nieder, Ellinor C. Haukland, Bård Mannsåker, Astrid Dalhaug
American Journal of Clinical Oncology.2023; 46(4): 178. CrossRef
Long-term disease-free survival following comprehensive involved site radiotherapy for oligometastases
Johnny Kao, Michelle Sahagian, Vani Gupta, Symeon Missios, Ashish Sangal
Frontiers in Oncology.2023;[Epub] CrossRef
Defining the expected 30-day mortality for patients undergoing palliative radiotherapy: A meta-analysis
Justin Henry Kutzko, Parvati Dadwal, Tanya Holt, Muhammed Aashiq Rahman, Syeda Farah Zahir, Brigid Hickey
Radiotherapy and Oncology.2022; 168: 147. CrossRef
Risk Stratification for Imminent Risk of Death at the Time of Palliative Radiotherapy Consultation
Susan Y. Wu, Emily Yee, Harish N. Vasudevan, Shannon E. Fogh, Lauren Boreta, Steve E. Braunstein, Julian C. Hong
JAMA Network Open.2021; 4(7): e2115641. CrossRef
Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review
André G. Gouveia, Dominic C.W. Chan, Peter J. Hoskin, Gustavo N. Marta, Fabio Trippa, Ernesto Maranzano, Edward Chow, Mauricio F. Silva
Radiotherapy and Oncology.2021; 163: 55. CrossRef
Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care
Matthew S. Ning, Prajnan Das, David I. Rosenthal, Bouthaina S. Dabaja, Zhongxing Liao, Joe Y. Chang, Daniel R. Gomez, Ann H. Klopp, G. Brandon Gunn, Pamela K. Allen, Paige L. Nitsch, Rachel B. Natter, Tina M. Briere, Joseph M. Herman, Rebecca Wells, Alber
Journal of the National Comprehensive Cancer Network.2021; 19(7): 805. CrossRef
Association of radiation dose intensity with overall survival in patients with distant metastases
Johnny Kao, Mark K. Farrugia, Samantha Frontario, Amanda Zucker, Emily Copel, John Loscalzo, Ashish Sangal, Boramir Darakchiev, Anurag Singh, Symeon Missios
Cancer Medicine.2021; 10(22): 7934. CrossRef
Palliative Radiotherapy
William Tristram Arscott, Jaclyn Emmett, Alireza Fotouhi Ghiam, Joshua A. Jones
Hematology/Oncology Clinics of North America.2020; 34(1): 253. CrossRef
Physician-Predicted Prognosis and Palliative Radiotherapy Treatment Utilization at the End of Life: An Audit of a Large Cancer Center Network
Adrianna E. Mojica-Márquez, Joshua L. Rodríguez-López, Ankur K. Patel, Diane C. Ling, Malolan S. Rajagopalan, Sushil Beriwal
Journal of Pain and Symptom Management.2020; 60(5): 898. CrossRef
External validation of life expectancy prognostic models in patients evaluated for palliative radiotherapy at the end‐of‐life
Adrianna E. Mojica‐Márquez, Joshua L. Rodríguez‐López, Ankur K. Patel, Diane C. Ling, Malolan S. Rajagopalan, Sushil Beriwal
Cancer Medicine.2020; 9(16): 5781. CrossRef
Replacing 30 Gy in 10 fractions with stereotactic body radiation therapy for bone metastases: A large multi-site single institution experience 2016–2018
Erin F. Gillespie, Kaitlyn Lapen, Diana G. Wang, N. Wijetunga, Gerri L. Pastrana, Marisa A. Kollmeier, Josh Yamada, Adam M. Schmitt, Daniel S. Higginson, Max Vaynrub, Ernesto Santos Martin, Amy J. Xu, C. Jillian Tsai, Divya Yerramilli, Oren Cahlon, T. Jon
Clinical and Translational Radiation Oncology.2020; 25: 75. CrossRef
Palliative radiotherapy near the end of life
Susan Y. Wu, Lisa Singer, Lauren Boreta, Michael A. Garcia, Shannon E. Fogh, Steve E. Braunstein
BMC Palliative Care.2019;[Epub] CrossRef
Blood Albumin As A Prognostic Factor Among Unselected Medically Treated Inpatients
Krzysztof Tojek, Gabriel Kowalczyk, Beata Czerniak, Wioletta Banaś, Beata Szukay, Wanda Korzycka-Wilińska, Zbigniew Banaszkiewicz, Jacek Budzyński
Biomarkers in Medicine.2019; 13(13): 1059. CrossRef

8,254 View
181 Download
23 Web of Science
18 Crossref

A Survey of Stereotactic Body Radiotherapy in Korea: Sun Hyun Bae, Mi-Sook Kim, Won Il Jang, Chul-Seung Kay, Woochul Kim, Eun Seog Kim, Jin Ho Kim, Jin Hee Kim, Kwang Mo Yang, Kyu Chan Lee, A Ram Chang, Sunmi Jo; Cancer Res Treat. 2015;47(3):379-386. Published online November 24, 2014; DOI: https://doi.org/10.4143/crt.2014.021

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to investigate the current status of stereotactic body radiotherapy (SBRT) in Korea. A nationwide survey was conducted by the Korean Stereotactic Radiosurgery Group of the Korean Society for Radiation Oncology (KROG 13-13).
Materials and Methods
SBRT was defined as radiotherapy with delivery of a high dose of radiation to an extracranial lesion in ≤ 4 fractions. A 16-questionnaire survey was sent by e-mail to the chief of radiation oncology at 85 institutions in June 2013.
Results
All institutions (100%) responded to this survey. Of these, 38 institutions (45%) have used SBRT and 47 institutions (55%) have not used SBRT. Regarding the treatment site, the lung (92%) and liver (76%) were the two most common sites. The most common schedules were 60 Gy/4 fractions for non-small cell lung cancer, 48 Gy/4 fractions for lung metastases, 60 Gy/3 fractions for hepatocellular carcinoma, and 45 Gy/3 fractions or 40 Gy/4 fractions for liver metastases. Four-dimensional computed tomography (CT) was the most common method for planning CT (74%). During planning CT, the most common method of immobilization was the use of an alpha cradle/vacuum-lock (42%).
Conclusion
Based on this survey, conduct of further prospective studies will be needed in order to determine the appropriate prescribed doses and to standardize the practice of SBRT.

Citations

Citations to this article as recorded by

Five-Day Spacing of Two Fractionated Ablative Radiotherapies Enhances Antitumor Immunity
Hyunkyung Kim, Eunju Lee, Haeun Cho, Eunji Kim, Won Il Jang, Kwangmo Yang, Yoon-Jin Lee, Tae-Jin Kim, Mi-Sook Kim
International Journal of Radiation Oncology*Biology*Physics.2024; 118(2): 498. CrossRef
Patterns of quality assurance and treatment planning for stereotactic body radiation therapy in India – A survey
Smriti Sharma, Ritu Raj Upreti, Rajesh A. Kinhikar, G. Sahani, P. K. Dash Sharma
Journal of Cancer Research and Therapeutics.2024;[Epub] CrossRef
Measuring dose in lung identifies peripheral tumour dose inaccuracy in SBRT audit
Maddison Shaw, Jessica Lye, Andrew Alves, Joerg Lehmann, Masoumeh Sanagou, Moshi Geso, Rhonda Brown
Physica Medica.2023; 112: 102632. CrossRef
Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium
Mihir D Shanker, Howard Y Liu, Yoo Young Lee, Katherine A Stuart, Elizabeth E Powell, Alan Wigg, David I Pryor
Journal of Gastroenterology and Hepatology.2021; 36(4): 873. CrossRef
A national survey on technology and quality assurance for stereotactic body radiation therapy
Carmelo Marino, Cristina Garibaldi, Ivan Veronese, Claudia Carbonini, Serenella Russo, Michele Stasi, Pietro Mancosu
Physica Medica.2019; 65: 6. CrossRef
Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07)
Hyejung Cha, Hee Chul Park, Jeong Il Yu, Tae Hyun Kim, Taek-Keun Nam, Sang Min Yoon, Won Sup Yoon, Jun Won Kim, Mi Sook Kim, Hong Seok Jang, Youngmin Choi, Jin Hee Kim, Chul Seung Kay, Inkyung Jung, Jinsil Seong
Cancer Research and Treatment.2017; 49(1): 61. CrossRef
Application of stereotactic body radiation therapy to cancer liver metastasis
Si-Yuan Zhang, Guang-Ying Zhu, Gong Li, Yi-Bao Zhang, Jian-Hao Geng
Cancer Letters.2016; 379(2): 225. CrossRef
Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group
Sun Hyun Bae, Mi-Sook Kim, Won Il Jang, Chul-Seung Kay, Woochul Kim, Eun Seog Kim, Jin Ho Kim, Jin Hee Kim, Kwang Mo Yang, Kyu Chan Lee, A Ram Chang, Sunmi Jo
Japanese Journal of Clinical Oncology.2016; 46(4): 363. CrossRef
Radiotherapy in the multidisciplinary treatment of liver cancer: a survey on behalf of the Italian Association of Radiation Oncology
Francesco Dionisi, Alessia Guarneri, Veronica Dell’Acqua, Mariacristina Leonardi, Rita Niespolo, Gabriella Macchia, Tiziana Comito, Maurizio Amichetti, Pierfrancesco Franco, Savino Cilla, Luciana Caravatta, Filippo Alongi, Giovanna Mantello
La radiologia medica.2016; 121(9): 735. CrossRef

13,518 View
101 Download
10 Web of Science
9 Crossref

First
Prev
Page of 1
Next
Last

Search